A Lawrence-based company is getting another $375,000 from the Kansas Bioscience Authority to continue development of a treatment to stop the advancement of osteoporosis and related bone disorders.

The grant, considered a partial match of a federal grant of $995,000, is OsteoGeneX’s second award from the authority. Last year the company received $130,000, which helped researchers identify several bone-building small molecules.

The latest grant is part of $3.7 million in financing announced this month by the authority, a $581 million initiative created by the Kansas Economic Growth Act of 2004 to boost bioscience research, assist start-ups and attract business expansion and attraction.

Other grants:

¢ $2.5 million for the Collaborative Cancer Research Initiative.

¢ $420,000 for ImmunoGenetix Therapeutics Inc., Lenexa, for work on its therapeutic vaccine for HIV.

¢ $200,000 for Vince and Associates Clinical Research, Overland Park, to boost capacity for clinical studies.

¢ $187,622 for TVAX Biomedical, Lenexa, for a clinical trial of a cancer treatment that uses a patient’s own immune cells to fight the disease.